CRISPR Therapeutics AG (NASDAQ: CRSP) kicked off on Tuesday, up 0.88% from the previous trading day, before settling in for the closing price of $44.24. Over the past 52 weeks, CRSP has traded in a range of $42.86-$91.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 33402.13%. While this was happening, its average annual earnings per share was recorded -165.70%. With a float of $81.70 million, this company’s outstanding shares have now reached $85.34 million.
Considering the fact that the conglomerate employs 407 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 30.6%, operating margin of -164.86%, and the pretax margin is -117.29%.
CRISPR Therapeutics AG (CRSP) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of CRISPR Therapeutics AG is 4.28%, while institutional ownership is 69.47%. The most recent insider transaction that took place on Dec 02 ’24, was worth 826,564. In this transaction Chief Executive Officer of this company sold 15,000 shares at a rate of $55.10, taking the stock ownership to the 181,540 shares. Before that another transaction happened on Nov 11 ’24, when Company’s Chief Executive Officer sold 30,000 for $55.62, making the entire transaction worth $1,668,678. This insider now owns 196,540 shares in total.
CRISPR Therapeutics AG (CRSP) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -165.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.70% during the next five years compared to 10.83% growth over the previous five years of trading.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
Take a look at CRISPR Therapeutics AG’s (CRSP) current performance indicators. Last quarter, stock had a quick ratio of 21.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.82, a number that is poised to hit -1.23 in the next quarter and is forecasted to reach -5.00 in one year’s time.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
Compared to the last year’s volume of 1.51 million, its volume of 1.92 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 12.07%. Additionally, its Average True Range was 2.39.
During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 10.64%, which indicates a significant decrease from 14.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.91% in the past 14 days, which was higher than the 49.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $48.65, while its 200-day Moving Average is $54.43. Nevertheless, the first resistance level for the watch stands at $45.23 in the near term. At $45.84, the stock is likely to face the second major resistance level. The third major resistance level sits at $46.75. If the price goes on to break the first support level at $43.71, it is likely to go to the next support level at $42.80. Should the price break the second support level, the third support level stands at $42.19.
CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats
The company with the Market Capitalisation of 3.81 billion has total of 85,353K Shares Outstanding. Its annual sales at the moment are 371,210 K in contrast with the sum of -153,610 K annual income. Company’s last quarter sales were recorded 600 K and last quarter income was -85,940 K.
